

Diabetic Retinopathy

Resource	Address
Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. <i>Am J Ophthalmol</i> . 1994;118:445-450.	https://www.ajo.com/article/S0002-9394(14)75794-0/pdf
American Diabetes Association (ADA). Medication & Treatments. Get to know your diabetes care team. Accessed April 11, 2022.	https://diabetes.org/healthy-living/medication-treatments/your-health-care-team
Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. <i>Ophthalmology</i> . 2013;120:2013-2022.	https://www.aaojournal.org/article/S0161-6420(13)00212-1/fulltext
Centers for Disease Control and Prevention (CDC). National diabetes statistics report 2020. Estimates of diabetes and its burden in the United States. Accessed April 11, 2022.	www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. <i>Lancet</i> . 2010;376:124-136.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)62124-3/fulltext
Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. <i>Ophthalmology</i> . 2014;121:1783-1789.	https://www.aaojournal.org/article/S0161-6420(14)00245-0/fulltext
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. <i>N Engl J Med</i> . 1993;329:977-986.	https://www.nejm.org/doi/full/10.1056/NEJM19930303291401
Diabetes In Control. Reduction in risk of diabetic complications per 1% decrease in HbA1c. April 22, 2002. Accessed April 11, 2022.	https://www.diabetesincontrol.com/reduction-in-risk-of-diabetic-complications-per-1-decrease-in/
Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. <i>Ophthalmology</i> . 2020;127:P66-P145.	https://www.aaojournal.org/article/S0161-6420(19)32092-5/fulltext

<p>Fox CR, Kronenberg K, Weiskopf ES. Using telemedicine to increase eye care screening & referral for people with diabetes. <i>J Pub Health Issue Pract.</i> 2019;3:137.</p>	<p>https://gexinonline.com/uploads/articles/Article_JPHIP-137.pdf</p>
<p>Gaedt Thorlund M, Borg Madsen M, Green A, Sjølie AK, Grauslund J. Is smoking a risk factor for proliferative diabetic retinopathy in type 1 diabetes? <i>Ophthalmologica.</i> 2013;230:50-54.</p>	<p>https://www.karger.com/Article/Abstract/350813</p>
<p>Gregori NZ. Diabetic Retinopathy: Causes, symptoms, Treatment. American Academy of Ophthalmology. <i>EyeSmart.</i> Published September 14, 2021.</p>	<p>www.aao.org/eye-health/diseases/diabetic-retinopathy-treatment</p>
<p>Gupta P, Aravindhan A, Gand ATL, et al. Association between the severity of diabetic retinopathy and falls in an Asian population with diabetes: The Singapore Epidemiology of Eye Diseases Study. <i>JAMA Ophthalmol.</i> 2017;135:1410-1416.</p>	<p>https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2663389</p>
<p>Ho AC, Albin TA, Brown DM, Boyer DS, Regillo CD, Heier JS. The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good. <i>JAMA Ophthalmol.</i> 2017;135:268-273.</p>	<p>https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2597594</p>
<p>International Council of Ophthalmology. ICO Guidelines for Diabetic Eye Care. Updated 2017.</p>	<p>https://icoph.org/eye-care-delivery/diabetic-eye-care/</p>
<p>Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. <i>Arch Ophthalmol.</i> 2012;1309:1145-1152.</p>	<p>https://jamanetwork.com/journals/jamaophthalmology/fullarticle/1149409</p>
<p>Mazhar K, Varma R, Choudhury F, et al. Severity of diabetic retinopathy and health-related quality of life: The Los Angeles Latino Eye Study. <i>Ophthalmology.</i> 2011;118:649-655.</p>	<p>https://www.aaojournal.org/article/S0161-6420(10)00819-5/fulltext</p>
<p>Morrison JL, Hodgson LA, Lim LL, Al-Qureshi S.. Diabetic retinopathy in pregnancy: A review. <i>Clin Exp Ophthalmol.</i> 2016;44:321-324.</p>	<p>https://onlinelibrary.wiley.com/doi/10.1111/ceo.12760</p>
<p>National Institutes of Health (NIH). National Eye Institute (NEI). Diabetic retinopathy. Last updated March 25, 2022.</p>	<p>https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy</p>
<p>National Institutes of Health (NIH). National Eye Institute (NEI). Injections to treat diabetic retinopathy and diabetic macular edema. Last updated May 29, 2019.</p>	<p>www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy/injections-treat-diabetic-retinopathy-and-diabetic-macular-edema</p>

Patel JI, Jenkins L, Benjamin L, Webber S. Dilated pupils and loss of accommodation following diode panretinal photocoagulation with sub-tenon local anaesthetic in four cases. <i>Eye (Lond)</i> . 2002;16:628-632.	https://www.nature.com/articles/6700004
Paulus YM, Blumenkranz MS. Proliferative and nonproliferative diabetic retinopathy. American Academy of Ophthalmology. <i>One® Network</i> . Published October 22, 2013.	www.aao.org/munnerlyn-laser-surgery-center/laser-treatment-of-proliferative-nonproliferative-
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. <i>Arch Ophthalmol</i> . 1985;103:1796-1806.	https://jamanetwork.com/journals/jamaophthalmology/article-abstract/635820
Reddy SV, Husain D. Panretinal Photocoagulation: A review of complications. <i>Semin Ophthalmol</i> . 2018;33:83-88.	https://www.tandfonline.com/doi/abs/10.1080/08820538.2017.1353820
Steinle N, Eichenbaum D, Goodale S, Ratliff AL, Shah AR. The business of medical retina: Overcoming payor challenges. <i>Retina Today</i> . Published October 1, 2020;(suppl).	https://retinatoday.com/issues/2020-oct-supplement3
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. <i>Lancet</i> . 1998;352:837-853.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)07019-6/fulltext
University of Michigan Health. Kellogg Eye Center. Diabetic retinopathy. Accessed April 11, 2022.	http://www.kellogg.umich.edu/patientcare/conditions/diabetic.retinopathy.html
Willis JR, Doan QV, Gleeson M, et al. Vision-related functional burden of diabetic retinopathy across severity levels in the United States. <i>JAMA Ophthalmol</i> . 2017;135:926-932.	https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2643965
Wykoff CC, Marcus DM, Midena E, et al. Intravitreal aflibercept injection in eyes with substantial vision loss after laser photocoagulation for diabetic macular edema: Subanalysis of the VISTA and VIVID randomized clinical trials. <i>JAMA Ophthalmol</i> . 2017;135:107-114.	https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2594015

Age-related Macular Degeneration

Resource	Address
<p>Cervantes-Castañeda RA, Banin E, Hemo I, Shpigel M, Averbukh E, Chowers I. Lack of benefit of early awareness to age-related macular degeneration. <i>Eye (Lond)</i>. 2008;22:777-781.</p>	<p>https://www.nature.com/articles/6702691</p>
<p>Gillies MC, Campain A, Barthelmes D, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: Data from an observational study. <i>Ophthalmology</i>. 2015;122:1837-1845.</p>	<p>https://www.aaojournal.org/article/S0161-6420(15)00458-3/fulltext</p>
<p>Ho AC, Albini TA, Brown DM, Boyer DS, Regillo CD, Heier JS. The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good. <i>JAMA Ophthalmol</i>. 2017;135:268-273.</p>	<p>https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2597594</p>
<p>Holz FG, Tadayoni R, Beatty S, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: Findings from the AURA study. <i>Br J Ophthalmol</i>. 2016;100:1623-1628.</p>	<p>https://bjo.bmj.com/content/100/12/1623</p>
<p>Flaxel CJ, Adelman RA, Bailey ST, et al. Age-Related Macular Degeneration Preferred Practice Pattern®. <i>Ophthalmology</i>. 2020;127:P1-P65.</p>	<p>https://www.aaojournal.org/article/S0161-6420(19)32091-3/fulltext</p>
<p>Keane PA, de Salvo G, Sim DA, Goverdhan S, Agrawal R, Tufail A, et al. Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration. <i>Clin Ophthalmol</i>. 2015;9:353-366.</p>	<p>https://www.dovepress.com/strategies-for-improving-early-detection-anddiagnosis-of-neovascul-peer-reviewed-fulltext-article-OPHTH</p>
<p>Lambert NG, ElShelmani H, Singh MK, et al. Risk factors and biomarkers of age-related macular degeneration. <i>Prog Retin Eye Res</i>. 2016;54:64-102.</p>	<p>https://www.sciencedirect.com/science/article/abs/pii/S135094621630012X?via%3Dihub</p>
<p>Llorente-González S, Hernandez M, González-Zamora J, et al. The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world. <i>Acta Ophthalmol</i>. 2021;100:e521-e531.</p>	<p>https://onlinelibrary.wiley.com/doi/10.1111/aos.14905</p>

Neely DC, Bray KJ, Huisinigh CE, Clark ME, McGwin G Jr, Owsley C. Prevalence of undiagnosed age-related macular degeneration in primary eye care. <i>JAMA Ophthalmol.</i> 2017;135:570-575.	https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2621881
Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. <i>Ophthalmology.</i> 2004;111:250-255.	https://www.aaojournal.org/article/S0161-6420(03)01195-3/fulltext
Pongsachareonnont P, Mak MYK, Hurst CP, Lam WC. Neovascular age-related macular degeneration: Intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. <i>Clin Ophthalmol.</i> 2018;12:1877-1885.	https://www.dovepress.com/neovascular-age-related-macular-degeneration-intraocular-inflammatory--peer-reviewed-fulltext-article-OPHTH
Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: Association with body mass index, waist circumference, and waist-hip ratio. <i>Arch Ophthalmol.</i> 2003;121:785-792.	https://jamanetwork.com/journals/jamaophthalmology/fullarticle/415389
Steinle N Eichenbaum D, Goodale S, Ratliff AL, Shah AR. The business of medical retina: Overcoming payor challenges. <i>Retina Today.</i> Published October 1, 2020;(suppl).	https://retinatoday.com/issues/2020-oct-supplement3
The Foundation of the American Society of Retina Specialists (ASRS). Intravitreal injections. Accessed April 11, 2022.	www.asrs.org/content/documents/fact-sheet-30-intravitreal-injections.pdf
Turbert D. Eye exam and vision testing basics. American Academy of Ophthalmology. <i>EyeSmart.</i> Published March 8, 2022.	www.aao.org/eye-health/tips-prevention/eye-exams-101
van Leeuwen R, Boekhoorn S, Vingerling JR, et al. Dietary intake of antioxidants and risk of age-related macular degeneration. <i>JAMA.</i> 2005;294:3101-3107.	https://jamanetwork.com/journals/jama/fullarticle/202098
Yeo NJY, Chan EJJ, Cheung C. Choroidal neovascularization: Mechanisms of endothelial dysfunction. <i>Front Pharmacol.</i> 2019;10:1363.	https://www.frontiersin.org/articles/10.3389/fphar.2019.01363/full
Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. <i>Ophthalmology.</i> 2013;120:122-129.	https://www.aaojournal.org/article/S0161-6420(12)00677-X/fulltext

Retinal Vein Occlusion

Resource	Address
Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. <i>N Engl J Med</i> . 1994;331:1480-1487.	https://www.nejm.org/doi/full/10.1056/NEJM199412013312203
Anderson FA, Spencer FA. Risk factors for venous thromboembolism. <i>Circulation</i> . 2003;107(23 suppl 1):I9-I16.	https://www.ahajournals.org/doi/10.1161/01.CIR.0000078469.07362.E6
Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. <i>Ophthalmology</i> . 2011;118:1594-1602.	https://www.aaojournal.org/article/S0161-6420(11)00181-3/fulltext
Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study. <i>Ophthalmology</i> . 2011;118:2041-2049.	https://www.aaojournal.org/article/S0161-6420(11)00224-7/fulltext
Christoffersen NLB, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. <i>Ophthalmology</i> . 1999;106:2054-2062.	https://www.aaojournal.org/article/S0161-6420(99)90483-9/fulltext
Fegan CD. Central retinal vein occlusion and thrombophilia. <i>Eye (Lond)</i> . 2002;16:98-106.	https://www.nature.com/articles/6700040
Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal Vein Occlusions Preferred Practice Pattern®. <i>Ophthalmology</i> . 2020;127:P288-P320.	https://www.aaojournal.org/article/S0161-6420(19)32096-2/fulltext
Kolar P. Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data. <i>J Ophthalmol</i> . 2014;724780.	https://www.hindawi.com/journals/joph/2014/724780/
Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. <i>Graefes Arch Clin Exp Ophthalmol</i> . 2006;244:309-315.	https://link.springer.com/article/10.1007/s00417-004-1087-4
Pinhas A, Dubow M, Shah N, et al. Fellow eye changes in patients with nonischemic central retinal vein occlusion: Assessment of perfused foveal microvascular density and identification of nonperfused capillaries. <i>Retina</i> . 2015;35:2028-2036.	https://journals.lww.com/retinajournal/Abstract/2015/10000/FELLOW_EYE_CHANGES_IN_PATIENTS_WITH_NONISCHEMIC.14.aspx

<p>Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. <i>Blood Transfus.</i> 2011;9:120-138.</p>	<p>https://www.bloodtransfusion.it/articolo.aspx?idart=002216</p>
<p>Schaab T, Padidam S, Gill MK. Navigating retinal imaging. <i>Ophthalmol Manage.</i> 2018;22:18-20, 22-24.</p>	<p>https://www.opthalmologymanagement.com/issues/2018/july-2018/navigating-retinal-imaging</p>
<p>Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: A systematic review and meta-analysis of prevalence, incidence, and risk factors. <i>J Glob Health.</i> 2019;9:010427.</p>	<p>https://jogh.org/documents/issue201901/jogh-09-010427.pdf</p>
<p>Steinle N Eichenbaum D, Goodale S, Ratliff AL, Shah AR. The business of medical retina: Overcoming payor challenges. <i>Retina Today.</i> Published October 1, 2020;(suppl).</p>	<p>https://retinatoday.com/issues/2020-oct-supplement3</p>